ClinicalTrials.gg
CompletedNCT03283722Updated Feb 11, 2025Results posted

PRESERVE-MITRAL Post-Market Registry

An observational study in Mitral Valve Disease, sponsored by Medtronic Cardiac Surgery. Completed at 12 sites in 3 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-02-11.

Sponsored by Medtronic Cardiac Surgery (part of Medtronic) · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years to 99 Years
Sex
All
01

Study summary

The objective of this registry is to gather data on the clinical outcomes of Medtronic mitral repair products (Profile 3D™ and CG Future® annuloplasty systems) in the approved intended use up to 12 months from the day of procedure

Read the detailed description

There is limited local evidence on mitral repair products in South Asia and a prospective post market registry will provide real world data on clinical outcomes.

Patients suffering from mitral valve disease and indicated for a mitral valve repair procedure with Profile 3D™ and CG Future® annuloplasty system as part of standard of care, in accordance with the product label indications (instructions for use), contraindications, and warnings will be considered for study participation.

PRESERVE-Mitral Registry is a prospective non-randomized, non-interventional, post-market registry

The objective of this registry is to gather data on the clinical outcomes of Medtronic mitral repair products (Profile 3D™ and CG Future® annuloplasty systems) in the approved intended use up to 12 months from the day of procedure

This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trail was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Heath Service Act or 42 CRF 11.24 and 11.44.)

02

Conditions studied

  • Mitral Valve Disease
03

In context

Lead sponsor

Medtronic Cardiac Surgery is the lead sponsor of 9 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients suffering from mitral valve disease and indicated for a mitral valve repair procedure with Profile 3D™ and CG Future® annuloplasty system as part of standard of care, in accordance with the product label indications (instructions for use), contraindications, and warnings

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with valvular insufficiency and/or stenosis and indicated for the reconstruction and/or remodeling of pathological mitral valves with Profile 3D™ and CG Future® annuloplasty systems
  2. Indications and provided in the product Instructions for Use
  3. Subject is 18 years of age or older
  4. The patient or his/her Legally Authorized Representative (LAR) has been informed about the nature of the registry and the patient for study participation has been obtained prior to performing any study-related procedures from the subject or Legally Authorized Representative, as per applicable local requirements

Exclusion criteria

Exclusion Criteria:

  1. as per instructions-for-use (IFU):

    1. Heavily calcified valves
    2. Valvular retraction with severely reduced mobility
    3. Active bacterial endocarditis
  2. Aortic valve replacement as concomitant procedure
  3. Already participating in another clinical study, possibly leading to bias and jeopardizing the scientific appropriate assessment of the study endpoints
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (actual)
Patient registry
No

Interventions

  • DeviceProfile 3D™ and CG Future® annuloplasty system

    Patients suffering from mitral valve disease and indicated for a mitral valve repair procedure with Profile 3D™ and CG Future® annuloplasty system as part of standard of care, in accordance with the product label indications (instructions for use), contraindications, and warnings

06

What researchers measure

Primary outcomes

  1. Improvement in Mitral Regurgitation (MR) Grade at 12-months Post Procedure

    This is determined by assessing the level of mitral valve regurgitation using echo, in subjects at 12-months post-procedure compared to the level at baseline. The levels of regurgitation, level 0-4, correspond to the American Society of Echocardiography (ASE) guidelines ranging from no MR, Mild MR, Moderate MR, Moderate- to-Severe MR and Severe MR. A percentage number is calculated to reflect how many participants had an MR improvement.

    Time frame: 12 months

  2. All Cause Mortality

    All deaths occurring from any cause 12-months post procedure

    Time frame: 12 months

Secondary outcomes

  1. Percentage of Participants With Improvement in MR Grade at Discharge and First Follow-up (3-6 Months)

    This was determined by assessing the level of mitral valve regurgitation using hemodynamic performance, in subjects at discharge and 3-6 months post-procedure compared to the level at baseline. The levels of regurgitation, level 0-4, correspond to the ASE guidelines ranging from no MR, Mild MR, Moderate MR, Moderate-to-Severe MR and Severe MR

    Time frame: At discharge from hospital (up to 7 days) and at first follow-up (3-6month)

  2. Improvement in NYHA Functional Class at Discharge, First Follow-up (3-6 Months) and Second Follow-up (12-months) Compared to Baseline.

    The percentage of subjects with an improved New York Heart Association NYHA functional class using a two-sided 95% exact binomial confidence internal measured at discharge, 3-6 months, and 12-months post-procedure and compared to baseline.

    Time frame: At discharge from hospital (up to 7 days), at first follow-up (3-6months), and at the second follow-up (12 months)

  3. Hospitalization for Heart Failure at 6 Months and at 12 Months Post Procedure

    Subjects who have a non-elective hospital admission for signs and symptoms related to heart failure that results in a one night stay (i.e., where the admission date and the discharge date differ by at least one calendar day)

    Time frame: 6 months and 12 months post procedure

  4. Mitral Valve Re-intervention at Discharge, 6 Months and at 12 Months Post Procedure

    Subject leaving the operating theater with an implanted Profile 3DTM or CG Future® annuloplasty system and later undergo any surgical or percutaneous interventional catheter procedure that repairs, otherwise alters or adjusts, or replaces the previously implanted annuloplasty system is considered a reoperation

    Time frame: At discharge from hospital (up to 7 days), at first follow-up (3-6months), and at the second follow-up (12 months)

  5. Stroke at 6 Months and at 12 Months Post Procedure

    Subjects had an acute episode of focal or global neurological dysfunction caused by brain, spinal cord, or retinal vascular injury as a result of hemorrhage or infarction, where the neurological dysfunction lasts for greater than 24-hours

    Time frame: 6 months and 12 months post procedure

  6. New Onset of Atrial Fibrillation, as Evaluated Through Follow up ECG at Discharge, First Follow up (3-6months) and at Second Follow up (12 Months)

    New onset of AF is defined as when the subject did not present with prior history of AF at baseline nor was AF detected at baseline visit, but AF did manifest post procedure and was either diagnosed during the study visits (discharge, 3-6 months or 12 months visit) or was otherwise diagnosed during the duration of subject participation in the study. The incidence of new onset AF will be evaluated at discharge, first follow up (3-6 months) and at second follow up (12 months). This endpoint is analyzed for the Successfully Implanted (IMP) cohort and provided as a Kaplan-Meier analysis.

    Time frame: At discharge from hospital, (up to 7 days), at first follow-up (3-6month), and at the second follow-up (12 months)

  7. Number of Attempts Required for Procedural Success

    Number of surgical attempts required for procedural implant success

    Time frame: Procedure (defined as the date of the first attempted procedure through subject leaving the operating theater with an implanted Profile 3D or CG Future annuloplasty system)

  8. Total Bypass Time During the Implant Procedure

    Total time a subject is on bypass time as a measure of procedural complexity

    Time frame: During the procedure as measured by standard operating procedures at the sites

07

Results

Posted Feb 11, 2025

Participant flow

Participant flow — Overall Study
MilestoneMitral Valve Repair With Profile 3D™ or CG Future® Annuloplasty System
Started200
Completed180
Not completed20

Outcome measures

PrimaryImprovement in Mitral Regurgitation (MR) Grade at 12-months Post Procedure

This is determined by assessing the level of mitral valve regurgitation using echo, in subjects at 12-months post-procedure compared to the level at baseline. The levels of regurgitation, level 0-4, correspond to the American Society of Echocardiography (ASE) guidelines ranging from no MR, Mild MR, Moderate MR, Moderate- to-Severe MR and Severe MR. A percentage number is calculated to reflect how many participants had an MR improvement.

Time frame:
12 months
Reported as:
Number · percentage of participants
Improvement in Mitral Regurgitation (MR) Grade at 12-months Post Procedure
percentage of participantsMitral Valve Repair With Profile 3D™ or CG Future® Annuloplasty System
Improvement in Mitral Regurgitation (MR) Grade at 12-months Post Procedure97.8 (93.8 to 99.6)
PrimaryAll Cause Mortality

All deaths occurring from any cause 12-months post procedure

Time frame:
12 months
Reported as:
Number · participants
All Cause Mortality
participantsMitral Valve Repair With Profile 3D™ or CG Future® Annuloplasty System
All Cause Mortality6
SecondaryPercentage of Participants With Improvement in MR Grade at Discharge and First Follow-up (3-6 Months)

This was determined by assessing the level of mitral valve regurgitation using hemodynamic performance, in subjects at discharge and 3-6 months post-procedure compared to the level at baseline. The levels of regurgitation, level 0-4, correspond to the ASE guidelines ranging from no MR, Mild MR, Moderate MR, Moderate-to-Severe MR and Severe MR

Time frame:
At discharge from hospital (up to 7 days) and at first follow-up (3-6month)
Reported as:
Number · percentage of patients with improved MR
Percentage of Participants With Improvement in MR Grade at Discharge and First Follow-up (3-6 Months)
percentage of patients with improved MRMitral Valve Repair With Profile 3D™ or CG Future® Annuloplasty System
Discharge100 (98.0 to 100)
3-6 month97.5 (93.8 to 99.3)
SecondaryImprovement in NYHA Functional Class at Discharge, First Follow-up (3-6 Months) and Second Follow-up (12-months) Compared to Baseline.

The percentage of subjects with an improved New York Heart Association NYHA functional class using a two-sided 95% exact binomial confidence internal measured at discharge, 3-6 months, and 12-months post-procedure and compared to baseline.

Time frame:
At discharge from hospital (up to 7 days), at first follow-up (3-6months), and at the second follow-up (12 months)
Reported as:
Number · percentage of participants
Improvement in NYHA Functional Class at Discharge, First Follow-up (3-6 Months) and Second Follow-up (12-months) Compared to Baseline.
percentage of participantsMitral Valve Repair With Profile 3D™ or CG Future® Annuloplasty System
Discharge73.4 (66.0 to 79.9)
3-6 Months84.5 (77.8 to 89.8)
12 Months83.8 (76.7 to 89.5)
SecondaryHospitalization for Heart Failure at 6 Months and at 12 Months Post Procedure

Subjects who have a non-elective hospital admission for signs and symptoms related to heart failure that results in a one night stay (i.e., where the admission date and the discharge date differ by at least one calendar day)

Time frame:
6 months and 12 months post procedure
Reported as:
Count of participants · Participants
Hospitalization for Heart Failure at 6 Months and at 12 Months Post Procedure
ParticipantsMitral Valve Repair With Profile 3D™ or CG Future® Annuloplasty System
6 Months4
12 Months1
SecondaryMitral Valve Re-intervention at Discharge, 6 Months and at 12 Months Post Procedure

Subject leaving the operating theater with an implanted Profile 3DTM or CG Future® annuloplasty system and later undergo any surgical or percutaneous interventional catheter procedure that repairs, otherwise alters or adjusts, or replaces the previously implanted annuloplasty system is considered a reoperation

Time frame:
At discharge from hospital (up to 7 days), at first follow-up (3-6months), and at the second follow-up (12 months)
Reported as:
Count of participants · Participants
Mitral Valve Re-intervention at Discharge, 6 Months and at 12 Months Post Procedure
ParticipantsMitral Valve Repair With Profile 3D™ or CG Future® Annuloplasty System
Discharge0
Discharge through 6 months0
12 months0
SecondaryStroke at 6 Months and at 12 Months Post Procedure

Subjects had an acute episode of focal or global neurological dysfunction caused by brain, spinal cord, or retinal vascular injury as a result of hemorrhage or infarction, where the neurological dysfunction lasts for greater than 24-hours

Time frame:
6 months and 12 months post procedure
Reported as:
Count of participants · Participants
Stroke at 6 Months and at 12 Months Post Procedure
ParticipantsMitral Valve Repair With Profile 3D™ or CG Future® Annuloplasty System
6 month2
12 month0
SecondaryNew Onset of Atrial Fibrillation, as Evaluated Through Follow up ECG at Discharge, First Follow up (3-6months) and at Second Follow up (12 Months)

New onset of AF is defined as when the subject did not present with prior history of AF at baseline nor was AF detected at baseline visit, but AF did manifest post procedure and was either diagnosed during the study visits (discharge, 3-6 months or 12 months visit) or was otherwise diagnosed during the duration of subject participation in the study. The incidence of new onset AF will be evaluated at discharge, first follow up (3-6 months) and at second follow up (12 months). This endpoint is analyzed for the Successfully Implanted (IMP) cohort and provided as a Kaplan-Meier analysis.

Time frame:
At discharge from hospital, (up to 7 days), at first follow-up (3-6month), and at the second follow-up (12 months)
Reported as:
Number · percentage of participants
New Onset of Atrial Fibrillation, as Evaluated Through Follow up ECG at Discharge, First Follow up (3-6months) and at Second Follow up (12 Months)
percentage of participantsMitral Valve Repair With Profile 3D™ or CG Future® Annuloplasty System
Discharge3.6 (1.6 to 7.8)
3-6 Months4.8 (2.4 to 9.6)
12 months4.8 (2.1 to 10.8)
SecondaryNumber of Attempts Required for Procedural Success

Number of surgical attempts required for procedural implant success

Time frame:
Procedure (defined as the date of the first attempted procedure through subject leaving the operating theater with an implanted Profile 3D or CG Future annuloplasty system)
Reported as:
Count of participants · Participants
Number of Attempts Required for Procedural Success
ParticipantsMitral Valve Repair With Profile 3D™ or CG Future® Annuloplasty System
One Attempt177
Two Attempts3
SecondaryTotal Bypass Time During the Implant Procedure

Total time a subject is on bypass time as a measure of procedural complexity

Time frame:
During the procedure as measured by standard operating procedures at the sites
Reported as:
Mean · Minutes
Total Bypass Time During the Implant Procedure
MinutesMitral Valve Repair With Profile 3D™ or CG Future® Annuloplasty System
Total Bypass Time During the Implant Procedure125.1 ± 47.0

Adverse events

Collected over 1 year. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Mitral Valve Repair With Profile 3D™ or CG Future® Annuloplasty System6/180 (3.3%)24/180 (13.3%)0/180 (0%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventMitral Valve Repair With Profile 3D™ or CG Future® Annuloplasty System
Cardiac Failure CongestiveCardiac disorders3/180
Cardiac FailureCardiac disorders2/180
DeathGeneral disorders2/180
Cerebrovascular AccidentNervous system disorders2/180
Pleural EffusionRespiratory, thoracic and mediastinal disorders2/180
ArrhythmiaCardiac disorders1/180
Atrial FibrillationCardiac disorders1/180
Atrial FlutterCardiac disorders1/180
Cardiac ArrestCardiac disorders1/180
Cardiopulmonary FailureCardiac disorders1/180

Baseline characteristics

200 total subjects enrolled, 184 had an attempted; and, 180 were successfully implanted and followed. Data reported is for the Successfully Implanted (IMP) cohort n=180.

Age, Continuous
Age, Continuous(years)Mitral Valve Repair With Profile 3D™ or CG Future® Annuloplasty System
Mean50.4 ± 15.0
Sex: Female, Male
Sex: Female, Male(Participants)Mitral Valve Repair With Profile 3D™ or CG Future® Annuloplasty System
Female65
Male115
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Mitral Valve Repair With Profile 3D™ or CG Future® Annuloplasty System
Region of Enrollment
Region of Enrollment(participants)Mitral Valve Repair With Profile 3D™ or CG Future® Annuloplasty System
Bangladesh23
Nepal13
India144
Weight
Weight(kg)Mitral Valve Repair With Profile 3D™ or CG Future® Annuloplasty System
Mean61.4 ± 12.2
Height
Height(cm)Mitral Valve Repair With Profile 3D™ or CG Future® Annuloplasty System
Mean161.4 ± 9.5
NYHA Classification
NYHA Classification(Participants)Mitral Valve Repair With Profile 3D™ or CG Future® Annuloplasty System
No Heart Failure0
Class I6
Class II91
Class III66
Class IV9
Cardiac Rhythm
Cardiac Rhythm(Participants)Mitral Valve Repair With Profile 3D™ or CG Future® Annuloplasty System
Atrial Fibrillation10
Atrial Flutter2
Normal Sinus Rhythm154
Other12

4 further baseline measures are reported on the registry.

08

Study locations

12 sites
  • National Heart Foundation Hospital & Research Institute
    Dhaka, 1216, Bangladesh
  • U. N. Mehta Institute of Cardiology and Research Centre
    Ahmedabad, Gujarat 380016, India
  • SAL Hospital & Medical Institute
    Ahmedabad, Gujarat 380054, India
  • EPIC Hospital
    Ahmedabad, Gujarat 380060, India
  • Sri Jayadeva Institute of Cardiovascular Sciences & Research
    Bangalore, Karnataka 560069, India
  • Narayana Institute of Cardiac Sciences
    Bangalore, Karnataka 560099, India
  • Amrita Institute of Medical Sciences and Research Center
    Kochi, Kerala 682041, India
  • P.D. Hinduja National Hospital and Medical Research Centre
    Mumbai, Maharashtra 400016, India
  • The Madras Medical Mission
    Chennai, Tamil Nadu 600037, India
  • G. Kuppuswamy Memorial Hospital
    Coimbatore, Tamil Nadu 641037, India
  • CARE Hospitals
    Hyderabad, Telangana 500034, India
  • Manmohan Cardiothoracic Vascular and Transplant Center
    Kathmandu, Nepal
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2017 to primary completion in Feb 2021, 46 months.

Results were first posted in Feb 2025, 4 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2017
First posted
Sep 14, 2017
StartActual
Apr 10, 2017
Primary completionActual
Feb 10, 2021
CompletionActual
Feb 10, 2021
Results first posted
Feb 11, 2025
Last update
Feb 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03283722
Responsible party
Sponsor
First posted
Sep 14, 2017
Start date
Apr 10, 2017
Primary completion
Feb 10, 2021
Completion
Feb 10, 2021
Results posted
Feb 11, 2025
Last update
Feb 11, 2025

Study contacts

Vinay Rajan, Ph.D
study chair · Medtronic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion